ClinicalTrials.gg
CompletedNCT03663582Updated Aug 4, 2020Results posted

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

A Phase 3 interventional study of Teduglutide and Syringe in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-08-04.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
19th of 20
7 · median 20
Started
2018
with 3 others
Phase 3
16 of 20
none open now
Registered
17th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 19th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 17th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The objectives of this clinical study are to evaluate the safety, efficacy, and pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS) who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment period.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to voluntarily provide written, signed, and to participate in the study.
  2. Male or female 16 years of age or older at the time of signing informed consent.
  3. Intestinal failure due to short bowel syndrome (SBS) as a result of major intestinal resection (example, due to injury, volvulus, vascular disease, cancer, Crohn's disease) that resulted in at least 12 continuous months of parenteral nutrition/intravenous (PN/IV) dependence at the time of informed consent.
  4. Parenteral nutrition requirement of at least 3 times per week during the week before the screening visit and during the 2 weeks prior to the baseline visit.
  5. Stable PN/IV requirement for at least 4 consecutive weeks immediately prior to the start of teduglutide treatment. Stability is defined as: a. Actual PN/IV usage is similar to prescribed PN/IV; b. Baseline (Visit 2) 48-hour oral fluid intake and urine output (I/O) volumes fall within +/- 25 percent (%) of the respective 48-hour I/O volumes at the last optimization visit; c. Urine output volume should NOT fall below 2 liter (L) and should not exceed 4 L per 48 hours at the last optimization visit, the stabilization visit, and the baseline visit.
  6. For participants with a history of Crohn's disease, clinical remission for at least 12 weeks prior to the baseline visit as demonstrated by clinical assessment, which may include procedure-based evidence of remission.
  7. Females of must agree to comply with the requirements of the protocol.
  8. An understanding, ability, and willingness to fully comply with study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Participation in a clinical study using an experimental drug within 30 days or 5.5 halflives, whichever is longer, prior to screening, or concurrent participation in any other clinical study.
  2. Use of glucagon-like peptide (GLP)-2 or human growth hormone or analogs of these hormones within the past 6 months.
  3. Use of octreotide, GLP-1 analogs, dipeptidyl peptidase-IV inhibitors, or enteral glutamine within 30 days.
  4. Previous use of teduglutide.
  5. Participants with active inflammatory bowel disease (IBD) or participants with IBD who received a change in therapy (example, azathioprine, anti- tumor necrosis factor (TNFs)) within the past 6 months.
  6. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, familial adenomatous polyposis, etc.
  7. Chronic intestinal pseudo-obstruction or severe dysmotility.
  8. intestinal stenosis or obstruction, or evidence of such on upper gastrointestinal (GI) series with small bowel follow-through, within the past 6 months.
  9. Major GI surgical intervention, including bowel lengthening procedures, within the past 3 months (insertion of feeding tube or endoscopic procedure is allowed).
  10. Unstable cardiac disease, (example, congestive heart failure, cyanotic disease, or congenital heart disease).
  11. Moderate or severe renal impairment, defined as less than (\<) 50 millilitre (ml)/ minute (min).
  12. Currently diagnosed with cancer or a history of any cancer except surgically curative skin cancer within the past 5 years.
  13. Severe hepatobiliary disease including: a. Total level greater than or equal to (>=) 2 times the (ULN); b. (AST) >=5 times ULN; c. Alanine aminotransferase (ALT) >=5 times ULN.
  14. Active clinically significant pancreatic disease, including clinical signs of pancreatitis associated with elevations in serum amylase or lipase >=2 times ULN.
  15. More than 4 SBS-related or PN/IV-related hospital admissions (example, central line associated bloodstream infection, bowel obstruction, severe fluid/electrolyte disturbances) within the past 12 months.
  16. Unscheduled hospitalization within 30 days prior to screening.
  17. Pregnant or lactating female.
  18. Any condition or circumstance that in the investigator's opinion put the participant at any undue risk, prevent completion of the study, or interfere with analysis of the study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Teduglutide 0.05 mg

    Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.

    Drug: Teduglutide · Device: Syringe · Device: Needle · Device: Vial Adapter for Device

Interventions

  • Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

  • DeviceSyringe

    Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).

  • DeviceNeedle

    Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.

  • DeviceVial Adapter for Device

    Vial adapter for device is approved for use in Japan by PMDA.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in weekly PS volume at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  2. Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

    Percent change from baseline in weekly PS volume at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  3. Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20

    Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.

    Time frame: Baseline, Week 20

  4. Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24

    Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.

    Time frame: Baseline, Week 24

  5. Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)

    Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  6. Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in days per week of PS at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  7. Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)

    Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  8. Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)

    Number of participants who were completely weaned off PS at Week 24/EOT was reported.

    Time frame: Week 24/EOT

  9. Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide

    AUC0-t of teduglutide was reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12

  10. Maximum Plasma Concentration (Cmax) of Teduglutide

    Cmax of teduglutide was reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12

  11. Time to Maximum Plasma Concentration (Tmax) of Teduglutide

    Tmax of teduglutide was reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12

  12. Terminal-phase Half-life (T1/2) of Teduglutide

    T1/2 of teduglutide was reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12

  13. Apparent Clearance (CL/F) of Teduglutide

    CL/F of teduglutide was reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12

  14. Apparent Volume of Distribution (Vz/F) of Teduglutide

    Vz/F of teduglutide was reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12

  15. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.

    Time frame: From start of study drug administration up to EOT/ET (up to Week 28)

  16. Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)

    12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.

    Time frame: From start of study drug administration up to EOT/ET (up to Week 28)

  17. Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  18. Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in pulse rate at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  19. Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in body temperature at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  20. Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in hemoglobin at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  21. Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in hematocrit at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  22. Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in serum blood urea nitrogen at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  23. Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in creatinine at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  24. Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in urine sodium at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  25. Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)

    Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.

    Time frame: EOT/ET (up to Week 28)

  26. Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in 48-hour urine output at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  27. Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in body weight at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  28. Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in BMI at EOT/ET was reported.

    Time frame: Baseline, EOT/ET (up to Week 28)

  29. Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)

    GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.

    Time frame: Week 24/ET

07

Results

Posted Aug 4, 2020

Participant flow

The study was conducted at 5 sites in Japan between 06 July 2018 (first participant first visit) and 06 August 2019 (last participant last visit).

Participant flow — Overall Study
MilestoneTeduglutide
Started7
Completed6
Not completed1
Withdrew: Physician decision1

Outcome measures

PrimaryChange From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

Change from baseline in weekly PS volume at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Liter per week (L/Week)
Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Liter per week (L/Week)Teduglutide
Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)-2.92 ± 3.463
PrimaryPercent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

Percent change from baseline in weekly PS volume at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Percent change
Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Percent changeTeduglutide
Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)-22.19 ± 24.953
PrimaryPercentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20

Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.

Time frame:
Baseline, Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20
Percentage of participantsTeduglutide
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 2066.7
PrimaryPercentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24

Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Percentage of participantsTeduglutide
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 2466.7
PrimaryPercentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)

Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)
Percentage of participantsTeduglutide
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)57.1
PrimaryChange From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)

Change from baseline in days per week of PS at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Days per Week
Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)
Days per WeekTeduglutide
Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)-0.43 ± 1.134
PrimaryChange From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)

Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Micromoles (mcmol)
Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)
Micromoles (mcmol)Teduglutide
Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)11.973 ± 11.7309
PrimaryNumber of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)

Number of participants who were completely weaned off PS at Week 24/EOT was reported.

Time frame:
Week 24/EOT
Reported as:
Count of participants · Participants
Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)
ParticipantsTeduglutide
Weaned Off Parenteral Support: No7
Weaned Off Parenteral Support: Yes0
PrimaryArea Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide

AUC0-t of teduglutide was reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Reported as:
Mean · Hour*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide
Hour*nanogram per milliliter (h*ng/mL)Teduglutide
Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide240.3 ± 80.651
PrimaryMaximum Plasma Concentration (Cmax) of Teduglutide

Cmax of teduglutide was reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Teduglutide
Nanograms per milliliter (ng/mL)Teduglutide
Maximum Plasma Concentration (Cmax) of Teduglutide49.50 ± 16.427
PrimaryTime to Maximum Plasma Concentration (Tmax) of Teduglutide

Tmax of teduglutide was reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Reported as:
Median · Hour
Time to Maximum Plasma Concentration (Tmax) of Teduglutide
HourTeduglutide
Time to Maximum Plasma Concentration (Tmax) of Teduglutide3.00 (1.87 to 5.92)
PrimaryTerminal-phase Half-life (T1/2) of Teduglutide

T1/2 of teduglutide was reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Reported as:
Median · Hour
Terminal-phase Half-life (T1/2) of Teduglutide
HourTeduglutide
Terminal-phase Half-life (T1/2) of Teduglutide1.09 (0.751 to 1.30)
PrimaryApparent Clearance (CL/F) of Teduglutide

CL/F of teduglutide was reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Reported as:
Mean · Milliliter per hour (mL/h)
Apparent Clearance (CL/F) of Teduglutide
Milliliter per hour (mL/h)Teduglutide
Apparent Clearance (CL/F) of Teduglutide10858.9 ± 4038.5
PrimaryApparent Volume of Distribution (Vz/F) of Teduglutide

Vz/F of teduglutide was reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Reported as:
Mean · Milliliter (mL)
Apparent Volume of Distribution (Vz/F) of Teduglutide
Milliliter (mL)Teduglutide
Apparent Volume of Distribution (Vz/F) of Teduglutide17167.4 ± 8371.9
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.

Time frame:
From start of study drug administration up to EOT/ET (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTeduglutide
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)7
PrimaryNumber of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)

12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.

Time frame:
From start of study drug administration up to EOT/ET (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)
ParticipantsTeduglutide
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)0
PrimaryChange From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)

Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Millimetre of mercury (mmHg)
Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)
Millimetre of mercury (mmHg)Teduglutide
Systolic Blood Pressure: EOT (up to Week 28)2.4 ± 19.37
Diastolic Blood Pressure: EOT (up to Week 28)6.6 ± 20.59
PrimaryChange From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)

Change from baseline in pulse rate at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Beats per minute (beats/min)
Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)
Beats per minute (beats/min)Teduglutide
Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)2.6 ± 9.88
PrimaryChange From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)

Change from baseline in body temperature at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Degree Celsius
Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)
Degree CelsiusTeduglutide
Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)-0.03 ± 0.411
PrimaryChange From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)

Change from baseline in hemoglobin at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Gram per liter (g/L)
Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)
Gram per liter (g/L)Teduglutide
Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)-3.9 ± 12.94
PrimaryChange From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)

Change from baseline in hematocrit at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Volume per volume (v/v)
Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)
Volume per volume (v/v)Teduglutide
Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)-0.014 ± 0.0355
PrimaryChange From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)

Change from baseline in serum blood urea nitrogen at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · mmol/L
Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)
mmol/LTeduglutide
Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)0 ± 0
PrimaryChange From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)

Change from baseline in creatinine at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Micromoles per liter (mcmol/L)
Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)
Micromoles per liter (mcmol/L)Teduglutide
Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)-5.6 ± 8.42
PrimaryChange From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)

Change from baseline in urine sodium at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)
millimoles per liter (mmol/L)Teduglutide
Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)-2.1 ± 64.92
PrimaryNumber of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)

Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.

Time frame:
EOT/ET (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)
ParticipantsTeduglutide
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)1
PrimaryChange From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)

Change from baseline in 48-hour urine output at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Milliliter per day (mL/day)
Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)
Milliliter per day (mL/day)Teduglutide
Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)213.57 ± 242.757
PrimaryChange From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)

Change from baseline in body weight at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · kilogram (kg)
Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)
kilogram (kg)Teduglutide
Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)0.164 ± 1.1146
PrimaryChange From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)

Change from baseline in BMI at EOT/ET was reported.

Time frame:
Baseline, EOT/ET (up to Week 28)
Reported as:
Mean · Kilograms per square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)
Kilograms per square meter (kg/m^2)Teduglutide
Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)0.07 ± 0.441
PrimaryNumber of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)

GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.

Time frame:
Week 24/ET
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)
ParticipantsTeduglutide
Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)0

Adverse events

Collected over From start of study drug administration up to EOT/ET (up to Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teduglutide0/7 (0%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventTeduglutide
Device related infectionInfections and infestations1/7
Medical device site infectionInfections and infestations1/7
Spinal compression fractureInjury, poisoning and procedural complications1/7
EpilepsyNervous system disorders1/7
Most frequent other events
Showing 10 of 25
Most frequent other events
EventTeduglutide
Abdominal distensionGastrointestinal disorders2/7
Injection site reactionGeneral disorders2/7
PyrexiaGeneral disorders2/7
NasopharyngitisInfections and infestations2/7
AnaemiaBlood and lymphatic system disorders1/7
PolycythaemiaBlood and lymphatic system disorders1/7
Back painMusculoskeletal and connective tissue disorders1/7
PhlebitisVascular disorders1/7
Abdominal painGastrointestinal disorders1/7
Abdominal pain lowerGastrointestinal disorders1/7

Baseline characteristics

Safety population included all participants in the intent-to-treat (ITT) population who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Teduglutide
Mean40.4 ± 8.92
Sex: Female, Male
Sex: Female, Male(Participants)Teduglutide
Female4
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Teduglutide
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Teduglutide
American Indian or Alaska Native0
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima-ken 734-8551, Japan
  • Hyogo College of Medicine Hospital
    Hyogo, 663-8501, Japan
  • Tohoku University Hospital
    Miyagi-Ken, 980-8574, Japan
  • Osaka University Hospital
    Osaka, 565-0871, Japan
  • Yokohama Municipal Citizen's Hospital
    Yokohama, 240-8555, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Aug 2019, 13 months.

Results were first posted in Aug 2020, 11 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Sep 10, 2018
StartActual
Jul 6, 2018
Primary completionActual
Aug 6, 2019
CompletionActual
Aug 6, 2019
Results first posted
Aug 4, 2020
Last update
Aug 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03663582
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 10, 2018
Start date
Jul 6, 2018
Primary completion
Aug 6, 2019
Completion
Aug 6, 2019
Results posted
Aug 4, 2020
Last update
Aug 4, 2020

Study contacts

Study Director
study director · Shire

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion